prescription-only oral iron treatment accepted by Health Canada. Accrufer® is expected to be licensed for commercialization in the first half of 2023. Doug Reynolds, President of KYE pharma, expressed delight over the accomplishment. He said, “The Shield and KYE teams worked tremendously hard to compile the Canadian NDS in a matter of months and I am extremely pleased to have achieved this milestone.”
José A. Menoyo, MD, Chief Medical Officer at Shield, expressed optimism over the achievement. He said, “We are delighted with the rapid progress made in partnership with KYE since the signing of the license agreement in January. Both organizations have demonstrated excellent collaboration and are driven to make Accrufer® available to patients in Canada with iron deficiency as quickly as possible. Shield Therapeutics is committed in bringing Accrufer®/Feraccru® to patients with iron deficiency around the world, and Canada is an important element of that mission.”
Accrufer®/Feraccru® (ferric maltol) is a unique, stable, non-salt-based oral medication for individuals with iron insufficiency, either with or without anemia. It has a unique absorption process as compared to other oral iron medications and has been found to be an effective and well-tolerated treatment in a variety of clinical trials. KYE Pharmaceuticals is a privately held firm based in Canada. Its mission is to deliver pharmaceuticals to the Canadian market to address clinically important and unmet medical needs.
